Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

"Clinical trials drive new, innovative tools to fight diseases, and overcoming barriers to access to clinical trials for under-represented communities is critical to improving health equity," said Andrea Wainer , executive vice president, Rapid and Molecular Diagnostics, and co-executive sponsor for the company's Diversity in Clinical Trials steering committee alongside Lisa Earnhardt , executive vice president of Medical Devices at Abbott. "Abbott has been focused on breaking down barriers and implementing new, sustainable partnerships and programs to drive even more diversity in our clinical trials and to ensure trials are offered in more places to reach underserved areas."

Improving Access Through New Clinical Research Models
Through a new five-year commitment, Abbott will work alongside the Institute for Health Equity at Norton Healthcare to build research program models that can be implemented by historically black colleges and universities (HBCUs) and clinics serving under-represented communities so they don't need to design and develop their own research programs from the ground up, which can be expensive and resource intensive.

Within the program, Abbott and Norton Healthcare will provide a roadmap of best practices to help community-based clinics create clinical trial research centers of excellence. The initiative will also provide grants to support the hiring and training of research coordinators and data managers and help guide the launch of research programs. Alongside building sustainable research programs, the effort aims to increase the number of trial sites that can reach underserved populations to reduce barriers to clinical trials.

The first pilot project stemming from the new grant will work to better connect more people from underrepresented communities to clinical trials. The first project will develop a new research center in Louisville, Ky. , focused on helping more African American patients access clinical trial opportunities. The project will specifically support patients in historically redlined areas of Louisville . "Redlining" is a discriminatory practice of withholding services from neighborhoods with significant numbers of racial and ethnic minorities and low-income residents. As a result, those communities have had reduced access to health services, including clinical research opportunities.

"As we focus on improving access to innovative health care options for patients who have been historically under-represented in clinical research, developing new models for research centers that can be implemented within rural or urban community clinics can have a profound impact on improving access to clinical trials for these patients," said Kelly McCants , M.D., a heart failure cardiologist and executive director of the Norton Heart & Vascular Institute Advanced Heart Failure & Recovery Program, who will help launch one of the pilot programs.

Expanding the Pool of Diverse Clinical Research Coordinators
Clinical research coordinators within healthcare clinics, doctor's offices and hospitals are essential to the success of clinical trials. They are key to improving the diversity of clinical trials because they serve as a central point of contact for patients, their families and the investigating physician leading the clinical trial. Through a partnership with Barnett International, Abbott is providing a comprehensive education program to support the training of new coordinators who are from diverse backgrounds and who will work with under-represented communities.

Upon completion of this course, participants will have a strong foundation in essential core areas of conducting clinical research. This includes training on study execution, the patient consent process, Good Clinical Practice guidelines, source documentation requirements and other regulatory required procedures. Offering training to clinical research coordinators with diverse backgrounds will address another key barrier for potential study participants.

New Diversity in Research Office within Abbott
Alongside new external partnerships and programs, the company has established a Diversity in Research Office to further Abbott's focus on driving diversity in the company's clinical trials and improving access to care among under-represented populations.

The new Diversity in Research Office will be led by Jennifer Jones-McMeans , Ph.D., divisional vice president of global clinical affairs for Abbott's vascular business, and Aparna Ahuja , M.D., divisional vice president for medical, clinical, and scientific affairs, Infectious Disease, for Abbott's rapid diagnostics business. The office will be responsible for ensuring that research efforts include diversity plans, key performance goals and foster collaboration across Abbott, the industry and regulatory bodies.

"Ensuring that clinical trials are as diverse as the people a product intends to serve is critically important in providing the best health care, so we're developing programs to address as many barriers as possible," said Jones-McMeans. "At Abbott, we've implemented programs that will increase the diversity of trials, including assessing how we conduct our own trials to make sure that we're doing all we can do to increase diversity in our clinical trials by increasing participation from under-served and under-represented populations."

Building Sustainable Change
Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation.

In the first year of the program, Abbott established a Diversity in Clinical Trials Medical Advisory Board comprised of external experts, an internal steering committee and has focused on increasing diversity enrollment in the company's own clinical trials. Through $5 million in grants, the company also sponsored more than 300 scholarships at the four HBCU medical schools and the National Black Nurses Association and National Association of Hispanic Nurses to support future leaders of clinical research.

To learn more about Abbott's Diversity in Research Initiative, visit https://www.abbott.com/diversity-in-clinical-trials.html .

Innovating for Greater Access and Equity in Health
Abbott's work to drive diversity in medical research is one example of the company innovating for greater access and affordability in health, the key priority of Abbott's 2030 Sustainability Plan . Abbott's ongoing commitment to address health equity challenges also includes targeted programs to create opportunities in STEM for women and underrepresented groups, build a more diverse healthcare supply chain and empower communities to break down social and economic barriers to better health.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at https://www.facebook.com/Abbott and on Twitter @AbbottNews .

View original content: https://www.prnewswire.com/news-releases/abbott-announces-new-partnerships-and-programs-to-advance-its-diversity-in-clinical-trials-initiative-301821930.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

abbott laboratories nyse:abt pharmaceutical investing Pharmaceutical Investing

ABT

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Aehr Test Systems Receives Orders of Over $2.3 million

Aehr Test Systems (NASDAQ:AEHR) has over 2,500 systems installed over the world that test optical and memory integrated circuits, semiconductors and reliability qualification equipment announced that it received over $2.3 million in orders for test and burn-in services. These orders came from a major manufacturer where Aehr’s services would be implemented for automotive products.

As quoted in the press release:

Keep reading...Show less

Cyclacel Reports Fourth Quarter And 2016 Financial Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its financial results for the fourth quarter and full year 2016.
As quoted in the press release:

The Company’s net loss applicable to common shareholders for the three months and year ended December 31, 2016 was $2.9 million and $12.0 million, respectively. As of December 31, 2016, cash and cash equivalents totaled $16.5 million.

Keep reading...Show less

Enanta Pharmaceuticals Announces AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir Shows High SVR Rates

Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR₁₂) with AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis. In a modified intent-to-treat (mITT) analysis, SVR₁₂was achieved in 100 percent (n=102/102) of severe CKD patients. The mITT analysis excludes patients who did not achieve SVR for reasons other than virologic failure. These new data from the Phase 3 EXPEDITION-4 study, evaluating patients with chronic HCV infection across all major genotypes (GT1-6) and severe CKD, will be presented as a late-breaker today at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
The EXPEDITION-4 results are the latest to be released from
registrational studies in AbbVie’s G/P clinical development program,
designed to investigate a faster path to virologic cure* for all major
HCV genotypes (GT1-6) and with the goal of addressing areas of continued
unmet need.
Glecaprevir (GLE), an NS3/4A protease inhibitor, is Enanta’s second
protease inhibitor being developed through its collaboration with
AbbVie. G/P is a once-daily regimen that combines two distinct antiviral
agents. G/P is a fixed-dose combination of glecaprevir (300mg) and
pibrentasvir (120mg), an NS5A inhibitor, dosed once-daily as three oral
tablets.
HCV is common among people with severe CKD, reaching prevalence of up to
80 percent in some regions of the world.¹ In the U.S., it is
estimated that over 500,000 people have both chronic HCV and CKD².
Some chronic HCV infected patients with severe CKD, particularly those
with GT2 and GT3 HCV infection, currently don’t have access to
direct-acting antivirals (DAAs). The development of new, safe and
effective regimens to treat HCV in these patients remains a critical
unmet medical need.³
The EXPEDITION-4 study enrolled 104 patients with severe chronic kidney
disease, including 85 patients (82 percent) who were receiving dialysis
at enrollment and 20 patients (19 percent) who had compensated
cirrhosis. The study also included those who were not cured with
previous treatment with sofosbuvir (SOF) plus ribavirin (RBV) or with
interferon (IFN) plus RBV, with or without SOF (44 patients, 42 percent).
The majority of treatment related adverse events (AEs) were mild or
moderate. The most commonly reported AEs included pruritus, fatigue and
nausea. Of the 24 percent of patients who experienced serious AEs, none
were considered related to G/P. Four AEs (4 percent) led to the
discontinuation of G/P and one patient died after achieving SVR₄
due to a serious AE (intracerebral hemorrhage) considered not-related to
G/P.
*Patients who achieve a sustained virologic response at 12 weeks post
treatment (SVR₁₂) are considered cured of
hepatitis C
About the EXPEDITION-4 Study
EXPEDITION-4 is a single-arm,
open-label, Phase 3 study evaluating the safety and efficacy of 12 weeks
of G/P in patients with GT1-6 chronic HCV infection and chronic kidney
disease, including those on dialysis. The primary endpoint is SVR₁₂.
Patients in the study had severe or end stage kidney disease (stage 4
and 5 CKD), with an eGFR < 30 mL/min/1.73 m2 required at screening.
Prior treatment in the study is defined as treatment with interferon
(IFN)/pegIFN ± RBV, or sofosbuvir (SOF) + RBV ± pegIFN therapy.
Additional information on the clinical trials for G/P is available at www.clinicaltrials.gov/.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on four disease
targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors that are members of the
direct-acting-antiviral (DAA) inhibitor classes designed for use against
the hepatitis C virus (HCV). These protease inhibitors, developed
through Enanta’s collaboration with AbbVie, include paritaprevir, which
is contained in AbbVie’s marketed DAA regimens for HCV, and glecaprevir
(ABT-493), Enanta’s second protease inhibitor product, which AbbVie has
developed in Phase 3 studies in a fixed-dose combination (G/P) with
pibrentasvir (ABT-530), AbbVie’s second NS5A inhibitor, and is preparing
for regulatory approval filings in the U.S., Europe and Japan.
Enanta has also discovered EDP-305, an FXR agonist product candidate for
NASH, currently in Phase 1 clinical development, as well as a
cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for
HCV, which is also in Phase 1 clinical development. In addition, Enanta
has early lead candidates for HBV and RSV in preclinical development.
Please visit www.enanta.com
for more information on Enanta’s programs and pipeline.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including
statements with respect to the prospects for AbbVie’s investigational
HCV treatment regimen containing glecaprevir (ABT-493). Statements that
are not historical facts are based on management’s current expectations,
estimates, forecasts and projections about Enanta’s business and the
industry in which it operates and management’s beliefs and assumptions.
The statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and assumptions,
which are difficult to predict. Therefore, actual outcomes and results
may differ materially from what is expressed in such forward-looking
statements. Important factors and risks that may affect actual results
include: the efforts of AbbVie (our collaborator developing glecaprevir)
to develop its glecaprevir/pibrentasvir(G/P) combination and
successfully obtain regulatory approval and commercialize it; the
regulatory and marketing efforts of others with respect to competitive
treatment regimens for HCV; regulatory and reimbursement actions
affecting G/P, any competitive regimen, or both; the need to obtain and
maintain patent protection for glecaprevir and avoid potential
infringement of the intellectual property rights of others; and other
risk factors described or referred to in “Risk Factors” in Enanta’s most
recent Form 10-K for the fiscal year ended September 30, 2015 and other
periodic reports filed more recently with the Securities and Exchange
Commission. Enanta cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These statements
speak only as of the date of this release, and Enanta undertakes no
obligation to update or revise these statements, except as may be
required by law.
________________________________________________
¹ Fabrizi F, Poordad FF, Martin P. Hepatitis C infection in
the patient with end stage renal disease. Hepatology. 2002;36(1):3-10.
² IMS Health, July 2016. Parsippany, NJ; Medivo, July 2016.
New York, NY (Estimate based on IMS Health Dx Medical Claims
12/2013-4/2016; IMS Health Life Link Patient Level Data 12/2013-4/2016;
Medivo Lab Data 12/2013-4/2016).
³ American Association for the Study of Liver Diseases.
Recommendations for Testing, Managing, and Treating Hepatitis C,
February 24, 2016, https://www.hcvguidelines.org/full-report/monitoring-patients-who-are-starting-hepatitis-c-treatment-are-treatment-or-have.
Accessed March 15, 2016.

Aehr Test Systems Announces Shipment of FOX-1P™ Single Wafer Test Systems to Lead Customer for Production Test and Burn-In Application

FREMONT, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) — Aehr Test Systems (NASDAQ:AEHR), a worldwide supplier of semiconductor test and burn-in equipment, today announced that it has begun production shipments to its initial lead customer for its FOX-1P single wafer test system and has shipped and received acceptance on the first production systems previously ordered by this customer. This follows the company’s announcement in July of the shipment of the initial FOX-1P system to this customer. The FOX-1P system is Aehr Test’s next generation single wafer test system for high volume production and early failure rate (EFR) test. Aehr Test expects to complete shipment of the remaining systems in backlog to the customer’s production site within its fiscal second quarter ending November 30, 2016.
Gayn Erickson, President and CEO of Aehr Test Systems, commented, “We are very pleased to begin shipment of production FOX-1P systems to this lead customer. In addition, we are pleased that this customer has expanded test applications for this system to include microcontrollers in addition to the initial target of non-volatile memories.”
The FOX-1P wafer test system is a member of Aehr Test’s next generation FOX-P family of wafer level test and burn-in systems and has more than 16,000 “Universal Channels” (I/O, Device Power Supply (DPS) or Per-pin Precision Measurement Unit (PPMU)). With the highest channel count available in the ATE industry, the flexibility of Aehr Test’s Universal Channel architecture, and the ability to perform both functional pattern verification and parametric testing at full-wafer parallel test, the FOX-1P system provides a highly differentiated solution from competitive alternatives for microcontroller test, flash wafer test, embedded memory or any wafer with long test times. These capabilities are particularly well suited for automotive applications where test and burn-in for early failure screening of devices is vital.
The FOX-1P is integrated with a high performance dual wafer probing platform developed by Semics, Inc. that incorporates two FOX-1P test systems in an industry leading small footprint for a high performance full featured wafer prober.
The FOX-P product family also includes multi-wafer FOX-XP test solutions that utilize the same Universal Channel technology. The FOX-XP systems are capable of functional test and burn-in/cycling of flash memories, microcontrollers, sensors, optical devices, laser diodes, VCSELs, LEDs and other leading edge ICs in wafer form before they are assembled into multi-die stacked packages or other applications where known good die are critical. These end applications can span enterprise solid state drives, automotive devices, highly valuable mobile applications, communications and mission critical integrated circuits and sensors.
The multi-wafer FOX-XP system utilizes the FOX-1P Channel Module to provide up to 2,048 Universal Channels per wafer, allowing the system to test all the devices on each wafer in parallel. This enhanced architecture allows customers to perform per pin parametric testing, more extensive digital pattern test with deeper data stimulus / capture memory (32M per pin), and deeper scan (768M) optimized for BIST/DFT testing. The multi-wafer FOX-XP system utilizes Aehr Test’s FOX WaferPak contactor, which provides a cost effective solution for making electrical contact with a full wafer or substrate in a multi-wafer environment which can be scaled to simultaneously test up to 54 wafers in a single test cell.
About Aehr Test Systems
Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic and memory integrated circuits and has an installed base of more than 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, capacity needs and opportunities for Aehr Test products in package and wafer level test. Aehr Test has developed and introduced several innovative products, including the ABTS^TM and FOX families of test and burn-in systems and WaferPak contactors. The ABTS systems are used in production and qualification testing of packaged parts for both low-power and high-power logic as well as memory devices. The FOX family of systems includes single and multi-wafer full wafer contact test and burn-in systems used for burn-in and functional test of complex devices, such as leading-edge memories, digital signal processors, microprocessors, microcontrollers and systems-on-a-chip. The WaferPak contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. For more information, please visit Aehr Test’s website at www.aehr.com.
Safe Harbor Statement
This press release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. These statements are based on information available to Aehr Test as of the date hereof and actual results could differ materially from those stated or implied due to risks and uncertainties. Forward-looking statements include statements regarding Aehr Test’s expectations, beliefs, intentions or strategies regarding the FOX products, including statements regarding future market opportunities and conditions, expected product shipment dates and customer orders or commitments. These risks and uncertainties include, without limitation, acceptance by customers of the FOX-1P system and the ability of new products to meet customer needs or perform as described, as well as general market conditions, customer demand and acceptance of Aehr Test’s products and Aehr Test’s ability to execute on its business strategy. See Aehr Test’s recent 10-K, 10-Q and other reports from time to time filed with the Securities and Exchange Commission for a more detailed description of the risks facing Aehr Test’s business. Aehr Test disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

Keep reading...Show less

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -
- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -
- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -
- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -
- PTC will host a conference call on Dec. 2, 2024 , at 8:30 am EST -

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments

Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer Share Q3 Results

Major pharmaceutical players Eli Lilly (NYSE:LLY), AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging from supply issues to financial constraints.

In its latest quarterly report, released on Wednesday (October 30), Eli Lilly missed on sales expectations for Zepbound, its popular weight-loss drug, and Mounjaro, its diabetes medication. Despite growing US demand for these products, supply chain management issues impacted the company’s ability to meet Wall Street's expectations.

According to Reuters, Eli Lilly dropped 8 percent on the news, reducing its market valuation by nearly US$70 billion.

Keep reading...Show less

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

1. Eli Lilly and Company (NYSE:LLY)

2. Novo Nordisk (NYSE:NVO)

3. Johnson & Johnson (NYSE:JNJ)

4. AbbVie (NYSE:ABBV)

5. Merck & Company (NYSE:MRK)

FAQs for pharmaceutical stocks

What does the pharmaceutical industry do?

What is the big pharma business model?

Who are the "Big 3" in pharma?

Which country is number one in the pharma industry?

What is the future of pharmaceuticals?

Are pharmaceutical stocks risky?

Big pharma ETFs

1. VanEck Pharmaceutical ETF (NASDAQ:PPH)

2. iShares US Pharmaceuticals ETF (ARCA:IHE)

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

5. KraneShares MSCI All China Health Care Index ETF (ARCA:KURE)

1. Cipher Pharmaceuticals (TSX:CPH)

2. NurExone Biologic (TSXV:NRX)

3. Satellos Bioscience (TSXV:MSCL)

4. Telescope Innovations (CSE:TELI)

Latest News

Latest Press Releases

Related News

TOP STOCKS